Praxis Precision Medicines Inc - Company Profile
Powered by 
All the sales intelligence you need on Praxis Precision Medicines Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Praxis Precision Medicines Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Praxis Precision Medicines Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Praxis Precision Medicines Inc (Praxis) is a clinical-stage biopharmaceutical company that leverages genetic epilepsy insights, develops therapies for central nervous system (CNS) disorders, and targets neuronal excitation-inhibition imbalance. Its pipeline products include ulixacaltamide which treats essential tremor; vormatrigine for focal onset seizures and generalized epilepsy; relutrigine which targets developmental and epileptic encephalopathies (DEE), and elsunersen for sodium voltage-gated channel alpha subunit 2 – developmental and epileptic encephalopathy; PRAX-020 which targets KCNT1 epilepsy; PRAX-050 which treats movement disorders; among others. It utilizes proprietary platform technologies, including the Cerebrum, small molecule platform for orally available precision therapies and the Solidus, antisense oligonucleotide (ASO) platform for targeted drug discovery. Praxis is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
99 High Street, 30th Floor, Boston, Massachusetts, 02110
Website
www.praxismedicines.com
Telephone
1 617 3008460
No of Employees
168
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PRAX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-65.9%
(2024 vs 2023)
Market Cap*
$8.9B
Net Profit Margin (2023)
XYZ
57.6%
(2024 vs 2023)
* As of and is in US$
Praxis Precision Medicines Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Platform: | Cerebrum |
| Cerebrum | Solidus |
| Solidus | DARE FOR MORE |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Praxis Precision Medicines Inc | H. Lundbeck AS | Stoke Therapeutics Inc | Xenon Pharmaceuticals Inc | Azevan Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Denmark | United States of America | Canada | United States of America |
| City | Boston | Valby | Bedford | Vancouver | Bethlehem |
| State/Province | Massachusetts | - | Massachusetts | British Columbia | Pennsylvania |
| No. of Employees | 168 | 5,000 | 170 | 358 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dean Mitchell | Chairman | Executive Board | 2020 | 70 |
| Marcio Souza | President; Director; Chief Executive Officer | Executive Board | 2020 | 47 |
| Timothy Kelly | Chief Financial Officer | Senior Management | 2021 | 53 |
| Megan Sniecinski | Chief Operating Officer | Senior Management | 2026 | 45 |
| Kelly McCue | Chief People Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer